Mathilde Ørbæk , Fernando Gonzalez-Ortiz , Rosa M.M. Gynthersen , Åse Bengaard Andersen , Kubra Tan , Ulf Andreasson , Kaj Blennow , Helene Mens , Henrik Zetterberg , Anne-Mette Lebech
{"title":"Plasma levels of the neuron damage markers brain-derived tau and glial fibrillary acidic protein in Lyme neuroborreliosis: A longitudinal study","authors":"Mathilde Ørbæk , Fernando Gonzalez-Ortiz , Rosa M.M. Gynthersen , Åse Bengaard Andersen , Kubra Tan , Ulf Andreasson , Kaj Blennow , Helene Mens , Henrik Zetterberg , Anne-Mette Lebech","doi":"10.1016/j.ttbdis.2025.102459","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>A reliable blood biomarker for neuroborreliosis (NB) has yet to be identified. This study investigated levels of neuron damage markers glial fibrillary acidic protein (GFAP) and brain-derived tau (BD-tau) over six months of follow-up in patients with NB. The aim was to evaluate the potential of these biomarkers for monitoring treatment response and prognostic purposes.</div></div><div><h3>Methods</h3><div>A retrospective longitudinal cohort study including plasma collected at diagnosis and approximately three- and six-months post diagnosis from adult NB patients enrolled at the Department of Infectious Diseases, Rigshospitalet between 2018 and 2020.</div><div>BD-tau concentrations were measured in-house using the Single Molecule Array (Simoa) HD-X platform, while GFAP concentrations were assessed on the same platform utilizing the GFAP Discovery Kit. Changes in biomarker concentrations were analyzed using linear mixed models with an unstructured covariance pattern, with follow-up included as a categorical fixed effect.</div></div><div><h3>Results</h3><div>A total of 23 patients (median age: 63 years; male/female ratio: 16/7) with 56 plasma samples were analyzed; 12 patients had complete samples. GFAP and BD-tau levels showed minimal variation throughout the study period. Patients with persistent symptoms had GFAP concentrations that were 55 % higher at diagnosis compared to those who fully recovered, though this difference was not statistically significant (<em>p</em> = 0.09). No significant associations were observed between biomarker levels and treatment response or long-term outcomes.</div></div><div><h3>Conclusions</h3><div>This longitudinal study did not find BD-tau or GFAP to be effective blood biomarkers for monitoring treatment response or predicting outcomes in NB.</div></div>","PeriodicalId":49320,"journal":{"name":"Ticks and Tick-borne Diseases","volume":"16 3","pages":"Article 102459"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ticks and Tick-borne Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877959X25000238","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Plasma levels of the neuron damage markers brain-derived tau and glial fibrillary acidic protein in Lyme neuroborreliosis: A longitudinal study
Background
A reliable blood biomarker for neuroborreliosis (NB) has yet to be identified. This study investigated levels of neuron damage markers glial fibrillary acidic protein (GFAP) and brain-derived tau (BD-tau) over six months of follow-up in patients with NB. The aim was to evaluate the potential of these biomarkers for monitoring treatment response and prognostic purposes.
Methods
A retrospective longitudinal cohort study including plasma collected at diagnosis and approximately three- and six-months post diagnosis from adult NB patients enrolled at the Department of Infectious Diseases, Rigshospitalet between 2018 and 2020.
BD-tau concentrations were measured in-house using the Single Molecule Array (Simoa) HD-X platform, while GFAP concentrations were assessed on the same platform utilizing the GFAP Discovery Kit. Changes in biomarker concentrations were analyzed using linear mixed models with an unstructured covariance pattern, with follow-up included as a categorical fixed effect.
Results
A total of 23 patients (median age: 63 years; male/female ratio: 16/7) with 56 plasma samples were analyzed; 12 patients had complete samples. GFAP and BD-tau levels showed minimal variation throughout the study period. Patients with persistent symptoms had GFAP concentrations that were 55 % higher at diagnosis compared to those who fully recovered, though this difference was not statistically significant (p = 0.09). No significant associations were observed between biomarker levels and treatment response or long-term outcomes.
Conclusions
This longitudinal study did not find BD-tau or GFAP to be effective blood biomarkers for monitoring treatment response or predicting outcomes in NB.
期刊介绍:
Ticks and Tick-borne Diseases is an international, peer-reviewed scientific journal. It publishes original research papers, short communications, state-of-the-art mini-reviews, letters to the editor, clinical-case studies, announcements of pertinent international meetings, and editorials.
The journal covers a broad spectrum and brings together various disciplines, for example, zoology, microbiology, molecular biology, genetics, mathematical modelling, veterinary and human medicine. Multidisciplinary approaches and the use of conventional and novel methods/methodologies (in the field and in the laboratory) are crucial for deeper understanding of the natural processes and human behaviour/activities that result in human or animal diseases and in economic effects of ticks and tick-borne pathogens. Such understanding is essential for management of tick populations and tick-borne diseases in an effective and environmentally acceptable manner.